NEW YORK (GenomeWeb News) - Transgenomic has named Craig Tuttle president and CEO, effective immediately.
 
Tuttle replaces Collin D'Silva, who resigned in April. Michael Summers, the company's chief financial officer, served as interim CEO. He will remain CFO, Transgenomic said. D'Silva now chairs Transgenomic's board.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.